Jonathan Janes

6.2k total citations · 3 hit papers
50 papers, 3.7k citations indexed

About

Jonathan Janes is a scholar working on Epidemiology, Dermatology and Surgery. According to data from OpenAlex, Jonathan Janes has authored 50 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Epidemiology, 11 papers in Dermatology and 10 papers in Surgery. Recurrent topics in Jonathan Janes's work include Sepsis Diagnosis and Treatment (25 papers), Dermatology and Skin Diseases (10 papers) and Hemodynamic Monitoring and Therapy (7 papers). Jonathan Janes is often cited by papers focused on Sepsis Diagnosis and Treatment (25 papers), Dermatology and Skin Diseases (10 papers) and Hemodynamic Monitoring and Therapy (7 papers). Jonathan Janes collaborates with scholars based in United States, Germany and United Kingdom. Jonathan Janes's co-authors include William L. Macias, Antonio Artigas, Jean-François Dhainaut, Mark D. Williams, Amy M. DeLozier, Ivor S. Douglas, Fabio P. Nunes, Burkhard Vangerow, Didier Payen and Jyrki Tenhunen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Diabetes Care.

In The Last Decade

Jonathan Janes

50 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drotrecogin Alfa (Activated) in Adults with Septic Shock

2012 877 citations V. Marco Ranieri, Bruce Thompson et al. New England Journal of Medicine profile →
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

2018 356 citations Daniel J. Wallace, Richard Furie et al. The Lancet profile →
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study

2018 250 citations Emma Guttman‐Yassky, Jonathan I. Silverberg et al. Journal of the American Academy of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Janes United States	25	1.4k	821	795	683	517	50	3.7k
Martin Kaul Germany	20	765 0.5×	868 1.1×	2.1k 2.7×	740 1.1×	43 0.1×	26	3.4k
Benjamin Trzaskoma United States	21	717 0.5×	79 0.1×	398 0.5×	408 0.6×	330 0.6×	49	2.4k
Michael Spannagl Germany	36	814 0.6×	195 0.2×	1.3k 1.7×	127 0.2×	114 0.2×	130	5.8k
for the Mexican Nephrology Collaborative Study Group United States	18	1.0k 0.7×	137 0.2×	514 0.6×	240 0.4×	45 0.1×	23	4.8k
S. Breanndan Moore United States	47	1.9k 1.3×	94 0.1×	1.3k 1.6×	850 1.2×	94 0.2×	132	8.1k
Gabrielle Morgan United States	22	1.0k 0.7×	101 0.1×	353 0.4×	466 0.7×	47 0.1×	64	2.4k
Antonio Brucato Italy	50	2.4k 1.7×	51 0.1×	1.2k 1.5×	1.9k 2.8×	239 0.5×	234	8.9k
Paula J. Santrach United States	32	990 0.7×	52 0.1×	134 0.2×	294 0.4×	173 0.3×	81	3.4k
James Yun United States	25	414 0.3×	214 0.3×	437 0.5×	384 0.6×	229 0.4×	166	2.5k
Ismaı̈l Elalamy France	32	343 0.2×	175 0.2×	241 0.3×	123 0.2×	52 0.1×	241	4.9k

Countries citing papers authored by Jonathan Janes

Since Specialization

Citations

This map shows the geographic impact of Jonathan Janes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Janes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Janes more than expected).

Fields of papers citing papers by Jonathan Janes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Janes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Janes. The network helps show where Jonathan Janes may publish in the future.

Co-authorship network of co-authors of Jonathan Janes

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Janes. A scholar is included among the top collaborators of Jonathan Janes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Janes. Jonathan Janes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reich, Kristian, Eric L. Simpson, Andreas Wollenberg, et al.. (2022). Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. British Journal of Dermatology. 188(2). 208–217. 11 indexed citations

Simpson, Eric L., Seth Forman, Jonathan I. Silverberg, et al.. (2021). Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). Journal of the American Academy of Dermatology. 85(1). 62–70. 106 indexed citations

King, Brett, Justin Ko, Seth Forman, et al.. (2021). Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study. Journal of the American Academy of Dermatology. 85(4). 847–853. 90 indexed citations

Guttman‐Yassky, Emma, Jonathan I. Silverberg, Osamu Nemoto, et al.. (2018). Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. Journal of the American Academy of Dermatology. 80(4). 913–921.e9. 250 indexed citations breakdown →

Wallace, Daniel J., Richard Furie, Yoshiya Tanaka, et al.. (2018). Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. 392(10143). 222–231. 356 indexed citations breakdown →

Man, M., Sandra Close, Andrew Shaw, et al.. (2012). Beyond single-marker analyses: mining whole genome scans for insights into treatment responses in severe sepsis. The Pharmacogenomics Journal. 13(3). 218–226. 27 indexed citations

Ranieri, V. Marco, Bruce Thompson, Philip S. Barie, et al.. (2012). Drotrecogin Alfa (Activated) in Adults with Septic Shock. New England Journal of Medicine. 366(22). 2055–2064. 877 indexed citations breakdown →

Dempfle, Carl-Erik, Elif Elmas, Andreas Link, et al.. (2011). Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism. Critical Care. 15(1). R23–R23. 1 indexed citations

Shorr, Andrew F., Jonathan Janes, Antonio Artigas, et al.. (2010). Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). Critical Care. 14(6). R229–R229. 14 indexed citations

10.

Beale, Richard, Jonathan Janes, Frank M. Brunkhorst, et al.. (2010). Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry. Critical Care. 14(3). R102–R102. 58 indexed citations

11.

Laterre, Pierre‐François, William L. Macias, Jonathan Janes, et al.. (2008). Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis. Critical Care. 12(5). R117–R117. 10 indexed citations

12.

Shorr, Andrew F., David R. Nelson, Duncan Wyncoll, et al.. (2008). Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). Critical Care. 12(2). R45–R45. 30 indexed citations

13.

Levi, Marcel, Mitchell M. Levy, Mark D. Williams, et al.. (2007). Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated). American Journal of Respiratory and Critical Care Medicine. 176(5). 483–490. 107 indexed citations

14.

Laterre, Pierre‐François, et al.. (2007). ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation*. Critical Care Medicine. 35(6). 1457–1463. 27 indexed citations

15.

Vangerow, Burkhard, Andrew F. Shorr, Duncan Wyncoll, et al.. (2007). The protein C pathway: implications for the design of the RESPOND study. Critical Care. 11(Suppl 5). S4–S4. 13 indexed citations

16.

Vincent, Jean‐Louis, Gordon R. Bernard, Richard Beale, et al.. (2005). Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*. Critical Care Medicine. 33(10). 2266–2277. 219 indexed citations

17.

Reinhart, Konrad, Jean‐Louis Vincent, Graham Ramsay, et al.. (2005). DATA FROM THE TOP TEN ENROLLING COUNTRIES CONTAINED IN THE PROGRESS (PROMOTING GLOBAL RESEARCH EXCELLENCE IN SEVERE SEPSIS) REGISTRY DEMONSTRATES VARIATIONS IN TREATMENT AND HIGH MORTALITY RATES. CHEST Journal. 128(4). 377S–377S. 1 indexed citations

18.

Levine, Robert L., S. C. Lowry, Jean-François Dhainaut, et al.. (2005). THE SAFETY OF DROTRECOGIN ALFA (ACTIVATED): INDEPTH DATA ANALYSIS SUGGESTS SURVIVAL BENEFIT INDEPENDENT OF SERIOUS ADVERSE EVENT OCCURRENCES. CHEST Journal. 128(4). 221S–221S. 1 indexed citations

19.

Dhainaut, Jean-François, Pierre‐François Laterre, Jonathan Janes, et al.. (2003). Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Medicine. 29(6). 894–903. 109 indexed citations

20.

Turley, Andrew, et al.. (2002). An assessment of the ability of impedance respirometry distinguish oesophageal from tracheal intubation. Anaesthesia. 57(11). 1090–1093. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact